Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis

PHASE4CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Arthritis, Juvenile Rheumatoid
Interventions
BIOLOGICAL

Measles, Mumps, Rubella vaccination

Dosage: 1 dose MMR vaccine, containing 5000 p.f.u. (plaque forming unit) life attenuated mumps virus (Jeryl-Lynn-strain), 1000 p.f.u. life attenuated measles virus (Moraten-strain) and 1000 p.f.u. life attenuated rubella virus (Wistar RA 27/3-strain) + 0.5 ml solution fluid Dosage form: subcutaneously frequency: once

Trial Locations (5)

6202 AZ

Academic hospital Maastricht, Maastricht

9700 RB

University Medical Center Groningen, Beatrix Children's Hospital, Groningen

3508 AB

University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht

1007 MB

VU University Medical Center Amsterdam, Amsterdam

3000 CB

Erasmus Medical Center Rotterdam; sophia Children's Hospital, Rotterdam

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University Medical Center Groningen

OTHER

collaborator

Amsterdam UMC, location VUmc

OTHER

collaborator

Maastricht University Medical Center

OTHER

collaborator

Erasmus Medical Center

OTHER

lead

N.M. Wulffraat

OTHER